{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:30:48Z","timestamp":1790170248114,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,3]],"date-time":"2027-03-03T00:00:00Z","timestamp":1804032000000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.oret.2025.10.006","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:39:15Z","timestamp":1760553555000},"page":"250-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["How to Judge Failure"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1351-4513","authenticated-orcid":false,"given":"Geoffrey K.","family":"Broadhead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiarn\u00e1n D.L.","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.10.006_bib1","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/aos.14177","article-title":"Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway","volume":"98","author":"J\u00f8rstad","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","article-title":"Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods","volume":"68","author":"Sorour","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/aos.12463","article-title":"Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration","volume":"92","author":"Broadhead","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5935\/0004-2749.20210036","article-title":"Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results","volume":"84","author":"Ertan","year":"2021","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/APO.0000000000000111","article-title":"Predictability of recalcitrance in neovascular age-related macular degeneration with indocyanine green angiography","volume":"4","author":"Rush","year":"2015","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.oret.2025.10.006_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/IAE.0000000000003729","article-title":"Sustained biweekly aflibercept for refractory neovascular age-related macular degeneration: the prospective TRISTAR study","volume":"43","author":"Schneider","year":"2023","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration","volume":"262","author":"Kataoka","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2013.02.017","article-title":"Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab","volume":"156","author":"Bakall","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.860784","article-title":"First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration","volume":"13","author":"Abdin","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oret.2025.10.006_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40942-022-00363-7","article-title":"Fluid dynamics between injections in incomplete anti-VEGF responders within neovascular age-related macular degeneration: a prospective observational study","volume":"8","author":"Gigon","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2025.10.006_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s10384-018-0619-0","article-title":"Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing","volume":"62","author":"Mimouni","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/IAE.0000000000000751","article-title":"Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy","volume":"36","author":"Sarao","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib13","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/OPTH.S424315","article-title":"One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration","volume":"17","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.10.006_bib15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/IAE.0000000000001726","article-title":"High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration","volume":"38","author":"You","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2147\/OPTH.S131343","article-title":"Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab","volume":"11","author":"Nixon","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib17","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.1038\/s41598-024-59632-0","article-title":"Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration","volume":"14","author":"Eckardt","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.10.006_bib18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/eye.2014.101","article-title":"Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results","volume":"28","author":"Grewal","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.10.006_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","article-title":"Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab","volume":"8","author":"Raimondi","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10792-024-03297-1","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration","volume":"44","author":"Aldhanhani","year":"2024","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/pharmaceutics16040470","article-title":"First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration","volume":"16","author":"Aljundi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.oret.2025.10.006_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4274\/tjo.galenos.2021.16578","article-title":"Prevalence of polypoidal choroidal vasculopathy in eyes with neovascular age-related macular degeneration resistant to intravitreal anti-VEGF treatment","volume":"52","author":"Mente\u015f","year":"2022","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3129\/i10-095","article-title":"Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab","volume":"46","author":"Almony","year":"2011","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib24","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","article-title":"Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema","volume":"38","author":"Borchert","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.10.006_bib25","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00417-021-05547-9","article-title":"Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration","volume":"260","author":"Broadhead","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib26","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s00417-020-04869-4","article-title":"The prognostic value of total macular external limiting membrane and ellipsoid zone damage for clinical outcome in treatment-resistant neovascular age-related macular degeneration","volume":"258","author":"Woronkowicz","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301096","article-title":"Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population","volume":"19","author":"Weng","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.10.006_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/OPTH.S188624","article-title":"Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration","volume":"13","author":"Taipale","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3928\/23258160-20130313-04","article-title":"SAVE (super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results","volume":"44","author":"Wykoff","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","article-title":"Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration","volume":"121","author":"Chang","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.10.006_bib31","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","article-title":"Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration","volume":"33","author":"Kumar","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10384-024-01134-7","article-title":"First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration","volume":"69","author":"Lee","year":"2024","journal-title":"Jpn J Ophthalmology"},{"key":"10.1016\/j.oret.2025.10.006_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.joco.2018.11.006","article-title":"Effects of subthreshold diode micropulse laser photocoagulation on treating patients with refractory diabetic macular edema","volume":"31","author":"Akhlaghi","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/tjo.tjo_85_20","article-title":"One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab","volume":"11","author":"Abouhussein","year":"2021","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/jop.2020.0004","article-title":"Choroidal thickness after dexamethasone implant or aflibercept in patients with diabetic macular edema persistent to ranibizumab","volume":"36","author":"Aksoy","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.oret.2025.10.006_bib35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10792-015-0155-6","article-title":"Efficacy of single-dose dexamethasone implantation in patients with persistent diabetic macular edema","volume":"36","author":"Ar\u0131kan Yorgun","year":"2016","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3928\/23258160-20170428-06","article-title":"Safety and efficacy of ziv-aflibercept in the treatment of refractory diabetic macular edema","volume":"48","author":"Ashraf","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00417-017-3624-y","article-title":"Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema","volume":"255","author":"Bahrami","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.14744\/bej.2023.73644","article-title":"Short-term effects of intravitreal dexamethasone implant on choroidal structure in eyes with refractory diabetic macular edema","volume":"8","author":"Bilici","year":"2023","journal-title":"Beyoglu Eye J"},{"key":"10.1016\/j.oret.2025.10.006_bib39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00592-018-1151-x","article-title":"Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema","volume":"55","author":"Busch","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.oret.2025.10.006_bib40","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1177\/11206721211024804","article-title":"Early treatment with dexamethasone intravitreal implants in diabetic macular edema: na\u00efve versus refractory patients","volume":"32","author":"Bux","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib41","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1177\/1120672119834182","article-title":"Analysis of anatomical biomarkers in subtypes of diabetic macular edema refractory to anti-vascular endothelial growth factor treated with dexamethasone implant","volume":"30","author":"Castro-Navarro","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib42","article-title":"Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario \u2013 the BRADIR study","volume":"36","author":"Chakraborty","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oret.2025.10.006_bib43","first-page":"1001","article-title":"Aflibercept vs. dexamethasone implant for recalcitrant diabetic macular edema in pseudophakic eyes - 1-year outcomes from a quazi-randomized study in India","volume":"72","author":"Chakraborty","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib44","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s13300-017-0332-x","article-title":"Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome","volume":"8","author":"Chatziralli","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.oret.2025.10.006_bib45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2021.01.022","article-title":"Association between obstructive sleep apnea and diabetic macular edema in patients with type 2 diabetes","volume":"226","author":"Chiang","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3928\/23258160-20200228-03","article-title":"Intravitreal ziv-aflibercept in patients with diabetic macular edema refractory to intravitreal bevacizumab","volume":"51","author":"Ebrahimiadib","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib47","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00417-019-04383-2","article-title":"Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial","volume":"257","author":"Entezari","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40942-022-00424-x","article-title":"Evaluation of the additive effect of interferon \u03b1 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema","volume":"8","author":"Faghihi","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2025.10.006_bib49","first-page":"1475","article-title":"Optical coherence tomography reflectivity in foveal cysts: a novel biomarker for early-response prediction of diabetic macular edema treated with dexamethasone","volume":"12","author":"Hwang","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.oret.2025.10.006_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/IAE.0000000000002196","article-title":"Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes: the international retina group real-life 24-month multicenter study. The IRGREL-DEX study","volume":"39","author":"Iglicki","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib51","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jfo.2023.04.001","article-title":"The additive effect of intravitreal dexamethasone combined with bevacizumab in refractory diabetic macular edema","volume":"46","author":"Karimi","year":"2023","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3459164","article-title":"Association between hyperreflective foci on spectral-domain optical coherence tomography and early recurrence of diabetic macular edema after intravitreal dexamethasone implantation","volume":"2019","author":"Kim","year":"2019","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3341\/kjo.2016.30.1.25","article-title":"Effect of posterior subtenon triamcinolone acetonide injection on diabetic macular edema refractory to intravitreal bevacizumab injection","volume":"30","author":"Kim","year":"2016","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12886-023-02831-6","article-title":"Comparison of the efficacy of intravitreal anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic macular edema","volume":"23","author":"Koc","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib55","article-title":"Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment","volume":"13","author":"Kwon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2025.10.006_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00417-017-3836-1","article-title":"Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success","volume":"256","author":"Laiginhas","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib57","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/jop.2016.0074","article-title":"Short-term outcomes of switching to ranibizumab therapy for diabetic macular edema in patients with persistent fluid after bevacizumab therapy","volume":"32","author":"Lee","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.oret.2025.10.006_bib58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3341\/kjo.2022.0109","article-title":"Comparison of optical coherence tomography biomarkers between bevacizumab good responders and nonresponders who were switched to dexamethasone implant in diabetic macular edema","volume":"37","author":"Lee","year":"2023","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6882607","article-title":"Choroidal structural changes of posterior subtenon triamcinolone acetonide injection in eyes with refractory diabetic macular edema","volume":"2022","author":"Liu","year":"2022","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib60","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/02713683.2021.1878540","article-title":"Dril influences short-term visual outcome after intravitreal corticosteroid injection for refractory diabetic macular edema","volume":"46","author":"Lu\u00eds","year":"2021","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.oret.2025.10.006_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5632634","article-title":"Switch to aflibercept in diabetic macular edema patients unresponsive to previous anti-VEGF therapy","volume":"2017","author":"Mira","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14740338.2024.2305361","article-title":"Influence of prior treatment protocol on intravitreal dexamethasone implant behavior in patients with diabetic macular edema in real-world practice","volume":"23","author":"Moreno-Martinez","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.oret.2025.10.006_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/OPTH.S280644","article-title":"Intravitreal ranibizumab or aflibercept after bevacizumab in diabetic macular edema: exploratory retrospective analysis","volume":"15","author":"Pessoa","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib64","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3390\/medicina59050982","article-title":"Combined treatment of persistent diabetic macular edema with aflibercept and triamcinolone acetonide in pseudophakic eyes","volume":"59","author":"Petrovic","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.oret.2025.10.006_bib65","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.3390\/jcm12062297","article-title":"Role of vitrectomy in nontractional refractory diabetic macular edema","volume":"12","author":"Ranno","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.oret.2025.10.006_bib66","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1364\/BOE.379150","article-title":"Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema","volume":"11","author":"Rasti","year":"2020","journal-title":"Biomed Opt Express"},{"key":"10.1016\/j.oret.2025.10.006_bib67","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/jcm13061819","article-title":"Real-world experience with brolucizumab compared to aflibercept in treatment-na\u00efve and therapy-refractory patients with diabetic macular edema","volume":"13","author":"R\u00fcbsam","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.oret.2025.10.006_bib68","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2147\/OPTH.S424314","article-title":"One year results of faricimab for aflibercept-resistant diabetic macular edema","volume":"17","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib69","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for treatment-resistant diabetic macular edema","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib70","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/ijo.IJO_459_20","article-title":"One-year outcomes of aflibercept for refractory diabetic macular edema in bevacizumab nonresponders","volume":"69","author":"Salimi","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib71","first-page":"43","article-title":"The efficacy of single-dose intravitreal dexamethasone implant for diabetic macular edema refractory to anti-VEGF therapy: real-life results","volume":"5","author":"Simsek","year":"2020","journal-title":"Beyoglu Eye J"},{"key":"10.1016\/j.oret.2025.10.006_bib72","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2147\/OPTH.S399981","article-title":"Characteristics and treatment patterns of patients with diabetic macular edema non-responsive to anti-vascular endothelial growth factor treatment in Ontario, Canada","volume":"17","author":"Somani","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib73","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/medicina60050732","article-title":"Treatment effects of switching to faricimab in eyes with diabetic macular edema refractory to aflibercept","volume":"60","author":"Tatsumi","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.oret.2025.10.006_bib74","first-page":"42","article-title":"Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema","volume":"36","author":"Tayyab","year":"2020","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.oret.2025.10.006_bib75","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2147\/OPTH.S110789","article-title":"Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema","volume":"10","author":"Thomas","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/02713683.2014.1002048","article-title":"Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment","volume":"41","author":"Totan","year":"2016","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.oret.2025.10.006_bib77","article-title":"Micropulse laser in patients with refractory and treatment-na\u00efve center-involved diabetic macular edema: short terms visual and anatomic outcomes","volume":"13","author":"Valera-Cornejo","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib78","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1089\/jop.2020.0130","article-title":"Assessment of inflammation biomarkers in diabetic macular edema treated with intravitreal dexamethasone implant","volume":"37","author":"Vural","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.oret.2025.10.006_bib79","first-page":"207","article-title":"Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab","volume":"38","author":"Konidaris","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/ceo.13636","article-title":"Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab","volume":"48","author":"Spooner","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib81","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41598-023-27753-7","article-title":"Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion","volume":"13","author":"Aljundi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.10.006_bib82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3341\/kjo.2017.31.2.108","article-title":"Dexamethasone intravitreal implant rescue treatment for bevacizumab refractory macular edema secondary to branch retinal vein occlusion","volume":"31","author":"Lee","year":"2017","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib83","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/IAE.0000000000000475","article-title":"The OMAR study: comparison of ozurdex and triamcinolone acetonide for refractory cystoid macular edema in retinal vein occlusion","volume":"35","author":"Ozkok","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12886-022-02245-w","article-title":"Treatment responses for branch retinal vein occlusion predicted by semi-automated fluorescein angiography quantification","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib85","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/15569527.2019.1614020","article-title":"Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study","volume":"38","author":"Georgalas","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.oret.2025.10.006_bib86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaophthalmol.2018.6111","article-title":"Month 12 outcomes after treatment change at month 6 among poor responders to aflibercept or bevacizumab in eyes with macular edema secondary to central or hemiretinal vein occlusion: a secondary analysis of the SCORE2 study","volume":"137","author":"Ip","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231194462","article-title":"Efficacy of subthreshold micropulse laser photocoagulation therapy versus anti-vascular endothelial growth factor therapy for refractory macular edema secondary to non-ischemic branch retinal vein occlusion","volume":"51","author":"Feng","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.oret.2025.10.006_bib88","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12886-024-03298-9","article-title":"Characteristics of macular edema associated with retinal vein occlusion showing poor anatomic response to three loading anti-vascular endothelial growth factor injections: an optical coherence tomography analysis","volume":"24","author":"Johari","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib89","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s40123-024-01010-0","article-title":"Factors affecting disease stability after intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration","volume":"13","author":"Kim","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2025.10.006_bib90","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.3390\/jcm13123434","article-title":"Switching from a fixed monthly aflibercept regimen to bi-monthly brolucizumab in refractory cases of neovascular age-related macular degeneration","volume":"13","author":"Kim","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.oret.2025.10.006_bib91","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.oret.2021.05.002","article-title":"Machine learning can predict anti-VEGF treatment demand in a treat-and-extend regimen for patients with neovascular AMD, DME, and RVO associated macular edema","volume":"5","author":"Gallardo","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib92","doi-asserted-by":"crossref","first-page":"226","DOI":"10.37845\/ret.vit.2024.33.37","article-title":"Comprasion of aflibersept and ranibizumab response in patients with DMO unresponsive to bevacizumab treatment: early versus late switch","volume":"33","author":"Arkan","year":"2024","journal-title":"J Retina Vitreous"},{"key":"10.1016\/j.oret.2025.10.006_bib93","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/bjo-2022-321766","article-title":"Macular thickness and its associated factors in a Chinese rural adult population: the Handan Eye Study","volume":"107","author":"Wu","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib94","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40942-020-00270-9","article-title":"Macular and choroidal thicknesses in a healthy Hispanic population evaluated by high-definition spectral-domain optical coherence tomography (SD-OCT)","volume":"6","author":"Cort\u00e9s","year":"2020","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2025.10.006_bib95","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.10.006_bib96","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ajo.2008.07.013","article-title":"Diabetic macular edema: what is focal and what is diffuse?","volume":"146","author":"Browning","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib97","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10792-025-03503-8","article-title":"Treating or tolerating persistent subretinal fluid in neovascular age-related macular degeneration: a systematic review of visual and anatomical outcomes with anti-VEGF therapy","volume":"45","author":"Asadi Khameneh","year":"2025","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2025.10.006_bib98","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.oret.2024.02.010","article-title":"Compartmental exudative dynamics in neovascular age-related macular degeneration: volumetric outcomes and impact of volatility in a phase III clinical trial","volume":"8","author":"Ehlers","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.10.006_bib99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/iovs.63.6.17","article-title":"The association of fluid volatility with subretinal hyperreflective material and ellipsoid zone integrity in neovascular AMD","volume":"63","author":"Ehlers","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.10.006_bib100","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.10.006_bib101","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1038\/s41433-023-02488-x","article-title":"Outcomes in patients with retinal vein occlusion with good baseline visual acuity","volume":"37","author":"Liu","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2025.10.006_bib102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/joco.joco_133_24","article-title":"Persistent diabetic macular edema: a comprehensive review of current treatments and emerging therapeutic options","volume":"36","author":"Faghihi","year":"2024","journal-title":"J Curr Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025004580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025004580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:10:32Z","timestamp":1777633832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025004580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2468653025004580"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.10.006","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Judge Failure","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}